Phase 1B Open-Label Study Of The Safety And Clinical Activity Of Crizotinib (PF-02341066) In Tumours With Genetic Events Involving The Anaplastic Lymphoma (ALK) Gene Locus
This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumours except non-small cell lung cancer that are positive for ALK.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society